Riluzole and other prognostic factors in ALS: a population-based registry study in Italy
- 252 Downloads
In this prospective population-based registry study on ALS survival, we investigated the role of riluzole treatment, together with other clinical factors, on the prognosis in incident ALS cases in Emilia Romagna Region (ERR), Italy.
A registry for ALS has been collecting all incident cases in ERR since 2009. Detailed clinical data from all patients diagnosed with ALS between 1.1.2009 and 31.12.2014 have been analyzed for this study, with last follow up date set at 31.12.2015.
During the 6 years of the study, there were 681 incident cases with a median tracheostomy-free survival of 40 months (95% CI 36–44) from onset and of 26 months (95% CI 24–30) from diagnosis; 573 patients (84.14%) were treated with riluzole, 207 (30.39%) patients underwent gastrostomy, 246 (36.12%) non invasive ventilation, and 103 (15.15%) invasive ventilation. Patients who took treatment for ≥ 75% of disease duration from diagnosis had a median survival of 29 months compared to 18 months in patients with < 75% treatment duration. In multivariable analysis, factors independently influencing survival were age at onset (HR 1.04, 95% CI 1.02–1.05, p < 0.001), dementia (HR 1.56, 95% CI 1.05–2.32, p = 0.027), degree of diagnostic certainty (HR 0.88, 95% CI 0.78–0.98, p = 0.021), gastrostomy (HR 1.46, 95% CI 1.14–1.88, p = 0.003), NIV (HR 1.43, 95% CI 1.12–1.82, p = 0.004), and weight loss at diagnosis (HR 1.05, 95% CI 1.03–1.07, p < 0.001), diagnostic delay (HR 0.98, 95% CI 0.97–0.99, p = 0.004), and % treatment duration (HR 0.98, 95% CI 0.98–0.99, p < 0.001).
Independently from other prognostic factors, patients who received riluzole for a longer period of time survived longer, but further population based studies are needed to verify if long-tem use of riluzole prolongs survival.
KeywordsAmyotrophic lateral sclerosis Survival Prognostic factors Therapeutic intervention Riluzole
The authors acknowledge ERRALS group: Project coordinator: J. Mandrioli. Collaborating centers: Department of Neuroscience, St. Agostino Estense Hospital, Azienda Ospedaliero Universitaria di Modena, Italy (J. Mandrioli, N. Fini, A. Fasano, E. Zucchi, A. Gessani, L. Ferri, S. Malerba, P. Nichelli). Department of Neurology, Bufalini Hospital, Cesena, Italy (Y. Handouk, S. Biguzzi, W. Neri). Department of Neurology, Forlì Hospital, Forlì, Italy (C. Guidi, W. Neri). Department of Neurosciences and Rehabilitation, St Anna Hospital, Ferrara (E. Sette, V. Tugnoli and M. R. Tola). Department of Neurology, G. Da Saliceto Hospital, Piacenza, Italy (E. Terlizzi, D. Guidetti). Department of Neurology, Infermi Hospital, Rimini, Italy (M. Currò Dossi, M. Pasquinelli, J. Andruccioli, A. Ravasio). Department of Neurology, Faenza and Ravenna Hospital, Ravenna, Italy (M. Casmiro,F. Rasi). Department of Neurology and IRCCS Istituto delle Scienze Neurologiche di Bologna, Bellaria Hospital, Bologna, Italy (F. Salvi, I. Bartolomei, R. Michelucci). Department of Biomedical and Neuromotor Science and IRCCS Istituto delle Scienze Neurologiche di Bologna, University of Bologna, Bologna, Italy (P. Avoni, S. De Pasqua, R. Liguori). Department of Neurology, IRCCS Arcispedale Santa Maria Nuova, Reggio Emilia, Italy (R. Rizzi, E. Canali, L. Codeluppi, F. Valzania). Department of Neuroscience, University of Parma, Parma, Italy (A. Taga, V. Pietrini, M. C. Trapasso, and L. Zinno). Department of Clinical and Experimental Medicine, Respiratory Disease and Lung Function Unit, University of Parma, Parma, Italy (M. Aiello). Department of Neurology, Fidenza Hospital, Parma, Italy (D. Medici, E. Chierici, E. Montanari). Department of Neurology, Carpi Hospital, Modena, Italy (M. Santangelo, S. Amidei). Department of Biomedical and Specialty Surgical Sciences, University of Ferrara, Ferrara, Italy (I. Casetta, M. Pugliatti, E. Della Coletta, V. Govoni, E. Granieri). Department of Neurology, Imola Hospital, Bologna, Italy (P. De Massis, V. Mussuto). Department of Neurology and IRCCS Istituto delle Scienze Neurologiche di Bologna, Maggiore Hospital, Bologna, Italy (A. Borghi, A. Gabellini, R. Michelucci). Neurology Unit, St. Orsola-Malpighi University Hospital, AOU di Bologna, Italy (R. Rinaldi, F. Cirignotta). Department of Hospital Services, Emilia Romagna Regional Health Authority, Bologna, Italy (S. Ferro). Neuroepidemiology Unit, IRCCS Istituto delle Scienze Neurologiche di Bologna, Italy (R. D’Alessandro). CREAGEN Research Center for Environmental, Genetic and Nutritional Epidemiology, University of Modena and Reggio Emilia, Modena, Italy.
Compliance with ethical standards
Conflicts of interest
The authors declare no conflicts of interest.
The study has been approved by the ethics committees of ERR and has therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki.
- 27.Thygesen SK, Christiansen CF, Christensen S, Lash TL, Sørensen HT (2011) The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of Patients. BMC Med Res Methodol 11:83. https://doi.org/10.1186/1471-2288-11-83 CrossRefPubMedPubMedCentralGoogle Scholar
- 28.Bensimon G, Lacomblez L, Meiningier V (1994) A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group 330:585–591Google Scholar
- 29.Miller RG, Jackson CE, Kasarskis EJ et al (2009) Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American. Neurology 73:1227–1233CrossRefPubMedPubMedCentralGoogle Scholar
- 32.Sívori M, Rodríguez GE, Pascansky D, Sáenz C, Sica RE (2007) Outcome of sporadic amyotrophic lateral sclerosis treated with non-invasive ventilation and riluzole. Med (B Aires) 67:326–330Google Scholar